- Davis to Serve on Company's Audit Committee; Expertise in Finance and SEC
Reporting Adds Depth and Breadth to Company's Board -
BOCA RATON, Fla., May 24 /PRNewswire-FirstCall/ -- Nabi
Biopharmaceuticals (Nasdaq: NABI) today announced that it has elected Peter
B. Davis to its board of directors. Most recently, Mr. Davis was vice
president of finance and chief financial officer at XOMA Ltd., a
biotechnology company that develops and commercializes antibody and other
protein-based biopharmaceuticals for cancer, immune disorders and
infectious diseases. With the addition of Mr. Davis, Nabi
Biopharmaceuticals' board now totals eight members. Mr. Davis is a
recognized veteran in the life sciences, with a particular expertise in
financial reporting and management.
"We are pleased to have someone of Peter's caliber join the Nabi
Biopharmaceuticals board," stated Thomas H. McLain, chairman, chief
executive officer and president, Nabi Biopharmaceuticals. "His expertise
and experience in finance will greatly supplement our Board and he will
play a critically important role on our Audit Committee. The knowledge he
will bring to Nabi Biopharmaceuticals is particularly important in today's
environment. We look forward to the many contributions he will make to our
company."
As vice president of finance and chief financial officer at XOMA, Mr.
Davis was responsible for all financial activities, corporate
communications and information technology. He also secured over $400
million in financing to support development activities. Prior to XOMA, he
was vice president of financial operations at Serono, Inc., a
pharmaceuticals company focusing on recombinant genetic engineering to
develop drugs. There, Mr. Davis was responsible for all financial aspects
of the $850 million operating group. In addition, he was vice president of
finance and chief financial officer at Akzo Nobel, Inc.;
controller-international at Stauffer chemical company; and has held several
positions at Pepsico, Inc.
Mr. Davis received his M.B.A at the University of Chicago and his B.A.
in mathematics from Northwestern University in Evanston, IL.
Statements in this press release about the company that are not
strictly historical are forward-looking statements and include statements
about our products in development, the market for such products, clinical
trials and studies, intellectual property position, and alliances and
partnerships. You can identify these forward-looking statements because
they involve our expectations, beliefs, plans, projections, or other
characterizations of future events or circumstances. These forward-looking
statements are not guarantees of future performance and are subject to
risks and uncertainties that may cause actual results to differ materially
from those in the forward- looking statements as a result of any number of
factors. These factors include, but are not limited to, risks relating to
the company's ability to advance the development of products currently in
the pipeline or in clinical trials; maintain the human and financial
resources to commercialize current products and bring to market products in
development; obtain regulatory approval for its products in the U.S.,
Europe or other markets; successfully develop, manufacture and market its
products; realize future sales growth for its biopharmaceutical products;
secure patent positions and prevail in patent litigation; raise additional
capital on acceptable terms; and re-pay its outstanding convertible senior
notes when due. Many of these factors are more fully discussed, as are
other factors, in the company's Annual Report on Form 10-K for the fiscal
year ended December 31, 2005 filed with the Securities and Exchange
Commission.
About Nabi Biopharmaceuticals
Nabi Biopharmaceuticals leverages its experience and knowledge in
powering the immune system to develop and market products that fight
serious medical conditions. The company has three products on the market
today: PhosLo(R) (calcium acetate), Nabi-HB(R) [Hepatitis B Immune Globulin
(Human)], and Aloprim(TM) (allopurinol sodium) for Injection. Nabi
Biopharmaceuticals is focused on developing products that address unmet
medical needs and offer commercial opportunities in our core business
areas: Gram-positive bacterial infections, hepatitis and transplant, kidney
disease (nephrology) and nicotine addiction. For a complete list of
pipeline products, please go to: http://www.nabi.com/pipeline/index.php .
The company is headquartered in Boca Raton, Florida. For additional
information about Nabi Biopharmaceuticals, please visit our website:
http://www.nabi.com .
SOURCE Nabi Biopharmaceuticals
 back to top
Related links:
http://www.nabi.com
http://www.nabi.com/pipeline/index.php
CONTACT:
Thomas E. Rathjen, Vice President, Investor
Relations, Nabi Biopharmaceuticals, +1-561-989-5800
|
